Issue 2

Echoes From the Weight-Loss Drug Boom

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Novo Plans to Acquire CDMO Catalent

To most of us, it came as a big surprise when Novo Holdings, the investment company that manages the assets and wealth of the Novo Nordisk Foundation, announced its intention to acquire Catalent for an all-cash sum of $16.5 billion, as it looks to meet the continuing demand of its weight loss and obesity-targeting drugs Wegovy and Ozempic.

Read more here.

FEATURED STORIES

Amgen’s MariTide Demonstrates Weight Loss Potential

Read more here.

Tirzepatide Lowers Blood Pressure of Obesity Patients

Read more here.

U.S. Government to Propose Significant Drug Price Cuts Under Medicare Negotiations

Read my here.

UK CMA Investigates Vifor Pharma Over Anti-Competitive Pricing

Read more here.

Funding to Battle Genetic Disorders & Cancer

Read more here.

Nanoform Announces Promising Clinical Results for Nanoenzalutamide

Read more here.

Lonza Announces Closure of Chinese Plant

Read more here.

Upperton Announces Sterile Drug Manufacturing Investment

Read more here.

Teva Announces it will Divest API Business as Part of ‘Pivot to Growth’ Strategy

Read more here.

Vegan & Ketogenic Diets Found to Alter the Immune System

Read more here.

IGC Pharma Progresses Towards Phase 1 Alzheimer’s Clinical Trial

Read more here.